Improving the health of children and families in the Asia-Pacific.

Our research provides evidence for policy and clinical practice to improve child health outcomes in resource-poor settings in the Asia-Pacific region. We partner with governments, local institutions and the World Health Organization (WHO) to answer questions needed for policy decision-making.

Our research started with evaluating reduced-dose pneumococcal conjugate vaccine (PCV) schedules, which helped to set the global PCV research agenda.

We are now evaluating the impact of PCV, rotavirus and a single-dose human papillomavirus (HPV) vaccine schedule in various Asia-Pacific countries; evaluating the use of azithromycin in labour to prevent maternal and infant infections; and developing approaches to describe and monitor equity and quality of care.

Our vision

  • Undertake high-priority, innovative, translational research to improve equitable health outcomes in low- and middle-income settings globally, with a particular focus on the Asia-Pacific region.
  • Develop the next generation of local and regional global health research leaders and support in-country research capacity.
  • Communicate our findings widely and ensure they are translated into local, regional and global policy and clinical practice by working in partnership with relevant stakeholders.

The emergence of COVID-19 has led us to rapidly utilise our expertise in vaccines, epidemiology and global child health to contribute to the pandemic response. Our group works with WHO, UNICEF, DFAT and local and regional governments to inform COVID-19 vaccine policies and decision-making.

Impact of Pneumococcal Vaccine in Laos

 New Vaccine Evaluation Project - Fiji

More information